| Ytd | -45.78% | |
| 1y | -73.94% |
| Open | 0.84 | Prev Close | 0.84 | Low | 0.84 | High | 0.88 | Mkt Cap | 234.19M |
| Vol | 2.06M | Avg Vol | 5.26M | EPS | -0.10 | P/E | -8.91 | Forward P/E | -7.15 |
| Beta | 0.26 | Short Ratio | 4.71 | Inst. Own | 27.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.15 | 200-d Avg | 1.42 | 1yr Est | 5.50 |
AKBA News
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's
U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consen
Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatm
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&
Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atient
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bi
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a b
CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today
CAMBRIDGE, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bio
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due
CAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a bio
Akebia Therapeutics NASDAQ: AKBA outlined its commercial priorities for Vafseo, the expected evoluti
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a b
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consen
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biop
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for it
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 pe
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnin
On Monday, 413 companies reached new 52-week lows.
On Friday morning, 446 companies hit new 52-week lows.
On Tuesday, 838 companies hit new 52-week lows.
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for
Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading.
On Tuesday, 540 companies set new 52-week lows.